Ensysce Biosciences Inc. (NASDAQ: ENSC) announced the enrollment of the first patient in its Phase 3 clinical trial for PF614 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE